James Lazarovits, Archon Biosciences CEO
October 30, 2024 07:00 AM EDT
Financing
Startups
AI

A start­up backed by No­bel win­ner David Bak­er takes an AI twist on an­ti­bod­ies

Andrew Dunn

Senior Biopharma Correspondent

The newest David Bak­er biotech start­up launched Wednes­day, as Ar­chon Bio­sciences has raised a $20 mil­lion seed round to de­vel­op what it be­lieves could be …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times